Trial reportThe Journal of clinical psychiatry2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Trial report in The Journal of clinical psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)
Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.The Cochrane database of systematic reviews · 2022Pooled it
- [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].Der Nervenarzt · 2019Pooled it
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.The Cochrane database of systematic reviews · 2018Pooled it
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.Schizophrenia (Heidelberg, Germany) · 2026Article
- Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database.BMC pharmacology & toxicology · 2025Article
- Putative role of immune reactions in the mechanism of tardive dyskinesia.Brain, behavior, & immunity - health · 2023Review
- Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.Cell reports. Medicine · 2023Article
- Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.Journal of patient-reported outcomes · 2023Article
- Movement disorders of the mouth: a review of the common phenomenologies.Journal of neurology · 2022Review
- Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents.Schizophrenia (Heidelberg, Germany) · 2022Article
- Effect of Varenicline on Tardive Dyskinesia: A Pilot Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Contrasting Typical and Atypical Antipsychotic Drugs.Focus (American Psychiatric Publishing) · 2021Article
- Recent Advances in the Pharmacology of Tardive Dyskinesia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Review
- Overcoming barriers to effective management of tardive dyskinesia.Neuropsychiatric disease and treatment · 2019Review
- Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.BMC psychiatry · 2018Article
- Review
- Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.CNS drugs · 2018Review
- Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.Neuropsychiatric disease and treatment · 2014Article
- Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects.Journal of psychiatry & neuroscience : JPN · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveWe compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD.
methodThis analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to all-cause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbaseline or showing changes in AIMS scores were evaluated with χ(2) tests. Data were collected from January 2001 to December 2004.
resultsTime to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ(2)(1) = 0.11, P = .743). Changes in PANSS scores were not significantly different (F(1,974) = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F(1,359) = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F(3,151) = 0.32, P = .811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a ≥ 50% decrease in AIMS score, and 7% showed a ≥ 50% increase in AIMS score.
conclusionsSchizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.
trial registrationclinicaltrials.gov Identifier: NCT00014001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.